食管肉瘤样癌诊治现状_West China Medical Journal

Authors：

印金平 ,  彭枫

四川大学华西医院胸部肿瘤科（成都 610041）;

Corresponding author：

彭枫, Email: pfwork@126.com

Keywords：

食管肉瘤样癌; 食管肿瘤; 肉瘤样癌; 手术治疗; 放射治疗; 化学疗法

DOI：

10.7507/1002-0179.201612111

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

食管肉瘤样癌是一种十分罕见的食管恶性肿瘤，无特异性临床症状及体征，主要表现为吞咽梗阻、胸骨后疼痛等；其生长速度较快，常呈息肉样生长；具有上皮性癌和梭性肉瘤样细胞 2 种成分，并以肉瘤样成分占优势，其发病原因及病理组织起源目前尚未明确；免疫组织化学检测癌成分常见细胞角蛋白及上皮膜抗原表达，肉瘤样成分常见波形纤维蛋白表达；治疗方式以手术为主，对放射治疗、化学疗法（化疗）较敏感，常用化疗方案为铂类联合氟尿嘧啶类或紫杉类的双药联合方案，其早期预后较食管鳞状细胞癌好。

Citation： 印金平, 彭枫. 食管肉瘤样癌诊治现状. West China Medical Journal, 2017, 32(11): 1814-1817. doi: 10.7507/1002-0179.201612111 Copy

1.	丁华野, 廖松林. 癌肉瘤和肉瘤样癌. 诊断病理学杂志, 1999(1): 60-61.
2.	方铣华, 林雪平. 肉瘤样癌及癌肉瘤的新认识. 肿瘤研究与临床, 2005, 17(2): 138-139.
3.	Raza MA, Mazzara PF. Sarcomatoid carcinoma of esophagus. Arch Pathol Lab Med, 2011, 135(7): 945-948.
4.	焦亮, 王涌泉. 肾肉瘤样癌研究进展. 临床与病理杂志, 2016, 36(4): 486-491.
5.	苌新伟, 马秀现, 李健, 等. 胆囊肉瘤样癌临床分析 12 例. 世界华人消化杂志, 2016, 24(13): 2063-2069.
6.	谭元元, 武世伍, 柴大敏, 等. 肺肉瘤样癌 10 例并临床病理分析. 临床与实验病理学杂志, 2016, 32(11): 1287-1289.
7.	王延林, 刘良发, 李亚卓, 等. 11 例头颈部肉瘤样癌临床分析. 中国耳鼻咽喉颅底外科杂志, 2013, 19(1): 9-14.
8.	陈鹏程, 陈奇勋, 倪型灏, 等. 食管肉瘤样癌的临床病理特征及预后分析. 中华肿瘤杂志, 2012, 34(4): 287-290.
9.	李春笋, 陈旭东, 何松, 等. 食管肉瘤样癌的临床病理特征及预后分析(附 20 例报告). 南京医科大学学报: 自然科学版, 2013, 33(11): 1566-1568.
10.	Iyomasa S, Kato H, Tachimori Y, et al. Carcinosarcoma of the esophagus: a twenty-case study. Jpn J Clin Oncol, 1990, 20(1): 99-106.
11.	王洪云, 候庆宝, 曹慧. 食管肉瘤样癌的临床特征与病理对照研究. 中国实用医药, 2014(29): 30-31.
12.	Li CS, Xu JZ, Tian SH, et al. Clinical pathology analysis of esophageal sarcomatoid carcinomn. Chinese-German J Clin Oncol, 2014, 13(5): 235-239.
13.	周实, 马树华, 李曼红. 食管癌肉瘤和肉瘤样癌 X 线、病理分析. 临床放射学杂志, 2009, 28(12): 1698-1699.
14.	余振, 程邦昌, 昌盛, 等. 食管癌肉瘤 22 例临床病理分析. 中华胃肠外科杂志, 2008, 11(3): 235-237.
15.	方铣华, 陈波, 吴梅娟. 食管肉瘤样癌. 河南肿瘤学杂志, 2002, 15(4): 237-239.
16.	赵尔增, 张建中, 郑燕华, 等. 食管肉瘤样癌临床病理和免疫组化分析. 肿瘤防治杂志, 2004, 11(12): 1304-1306.
17.	Wang L, Lin Y, Long H, et al. Esophageal carcinosarcoma: a unique entity with better prognosis. Ann Surg Oncol, 2013, 20(3): 997-1004.
18.	Sano A, Sakurai S, Kato H, et al. Clinicopathological and immunohistochemical characteristics of esophageal carcinosarcoma. Anticancer Res, 2009, 29(8): 3375-3380.
19.	黄志军, 邱建龙, 郭启祥. 14 例食管肉瘤样癌的临床病理分析. 临床肿瘤学杂志, 2006, 11(11): 844-845.
20.	Kashiwabara K, Sano T, Oyama T, et al. A case of esophageal sarcomatoid carcinoma with molecular evidence of a monoclonal origin. Pathol Res Pract, 2001, 197(1): 41-46.
21.	Ohtaka M, Kumasaka T, Nobukawa B, et al. Carcinosarcoma of the esophagus characterized by myoepithelial and ductal differentiations. Pathol Int, 2002, 52(10): 657-663.
22.	Lam KY, Law SY, Loke SL, et al. Double sarcomatoid carcinomas of the oesophagus. Pathol Res Pract, 1996, 192(6): 604-609.
23.	Nakagawa S, Yabusaki H, Tanaka O. Rapid-growth carcinosarcoma of the esophagus arising from 0-Ⅱc squamous cell carcinoma after definitive chemoradiotherapy: a case report. Esophagus, 2009, 6(2): 123-126.
24.	Ogasawara N, Tamura Y, Funaki Y, et al. Rapidly growing esophageal carcinosarcoma reduced by neoadjuvant radiotherapy alone. Case Rep Gastroenterol, 2014, 8(2): 227-234.
25.	Lauwers GY, Grant LD, Scott GV, et al. Spindle cell squamous carcinoma of the esophagus: analysis of ploidy and tumor proliferative activity in a series of 13 cases. Hum Pathol, 1998, 29(8): 863-868.
26.	许丰, 吴杨庆, 马涵, 等. 食管肉瘤样癌内镜切除的临床价值初步探讨. 中华消化内镜杂志, 2016, 33(5): 334-336.
27.	Zuiki T, Hosoya Y, Ui T, et al. Therapeutic effectiveness of chemoradiotherapy for carcinosarcoma of the esophagus: two case reports and a review of the literature. Esophagus, 2009, 6(3): 189-195.
28.	Kobayashi D, Koike M, Kodera Y, et al. Carcinosarcoma of the esophagus treated with chemoradiotherapy: report of four cases. Esophagus, 2010, 7(2): 119-125.
29.	Joseph RW, Millis SZ, Carballido EM, et al. PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation. Cancer immunology research, 2015, 3(12): 1303-1307.
30.	Vieira T, Antoine M, Hamard C, et al. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer, 2016, 98: 51-58.
31.	Velcheti V, Rimm DL, Schalper KA. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) J Thorac Oncol, 2013, 8(6): 803-805.
32.	Kim S, Kim MY, Koh J, et al. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas. Eur J Cancer, 2015, 51(17): 2698-2707.
33.	Pelosi G, Gasparini P, Conte D, et al. Synergistic activation upon Met and ALK coamplification sustains targeted therapy in sarcomatoid carcinoma, a deadly subtype of lung cancer. J Thorac Oncol, 2016, 11(5): 718-728.
34.	Zhang HL, Zhu Y, Qin XJ, et al. c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature. Clin Genitourin Cancer, 2013, 11(2): 134-140.
35.	Geynisman DM. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur Urol, 2015, 68(5): 912-914.

1. 丁华野, 廖松林. 癌肉瘤和肉瘤样癌. 诊断病理学杂志, 1999(1): 60-61.
2. 方铣华, 林雪平. 肉瘤样癌及癌肉瘤的新认识. 肿瘤研究与临床, 2005, 17(2): 138-139.
3. Raza MA, Mazzara PF. Sarcomatoid carcinoma of esophagus. Arch Pathol Lab Med, 2011, 135(7): 945-948.
4. 焦亮, 王涌泉. 肾肉瘤样癌研究进展. 临床与病理杂志, 2016, 36(4): 486-491.
5. 苌新伟, 马秀现, 李健, 等. 胆囊肉瘤样癌临床分析 12 例. 世界华人消化杂志, 2016, 24(13): 2063-2069.
6. 谭元元, 武世伍, 柴大敏, 等. 肺肉瘤样癌 10 例并临床病理分析. 临床与实验病理学杂志, 2016, 32(11): 1287-1289.
7. 王延林, 刘良发, 李亚卓, 等. 11 例头颈部肉瘤样癌临床分析. 中国耳鼻咽喉颅底外科杂志, 2013, 19(1): 9-14.
8. 陈鹏程, 陈奇勋, 倪型灏, 等. 食管肉瘤样癌的临床病理特征及预后分析. 中华肿瘤杂志, 2012, 34(4): 287-290.
9. 李春笋, 陈旭东, 何松, 等. 食管肉瘤样癌的临床病理特征及预后分析(附 20 例报告). 南京医科大学学报: 自然科学版, 2013, 33(11): 1566-1568.
10. Iyomasa S, Kato H, Tachimori Y, et al. Carcinosarcoma of the esophagus: a twenty-case study. Jpn J Clin Oncol, 1990, 20(1): 99-106.
11. 王洪云, 候庆宝, 曹慧. 食管肉瘤样癌的临床特征与病理对照研究. 中国实用医药, 2014(29): 30-31.
12. Li CS, Xu JZ, Tian SH, et al. Clinical pathology analysis of esophageal sarcomatoid carcinomn. Chinese-German J Clin Oncol, 2014, 13(5): 235-239.
13. 周实, 马树华, 李曼红. 食管癌肉瘤和肉瘤样癌 X 线、病理分析. 临床放射学杂志, 2009, 28(12): 1698-1699.
14. 余振, 程邦昌, 昌盛, 等. 食管癌肉瘤 22 例临床病理分析. 中华胃肠外科杂志, 2008, 11(3): 235-237.
15. 方铣华, 陈波, 吴梅娟. 食管肉瘤样癌. 河南肿瘤学杂志, 2002, 15(4): 237-239.
16. 赵尔增, 张建中, 郑燕华, 等. 食管肉瘤样癌临床病理和免疫组化分析. 肿瘤防治杂志, 2004, 11(12): 1304-1306.
17. Wang L, Lin Y, Long H, et al. Esophageal carcinosarcoma: a unique entity with better prognosis. Ann Surg Oncol, 2013, 20(3): 997-1004.
18. Sano A, Sakurai S, Kato H, et al. Clinicopathological and immunohistochemical characteristics of esophageal carcinosarcoma. Anticancer Res, 2009, 29(8): 3375-3380.
19. 黄志军, 邱建龙, 郭启祥. 14 例食管肉瘤样癌的临床病理分析. 临床肿瘤学杂志, 2006, 11(11): 844-845.
20. Kashiwabara K, Sano T, Oyama T, et al. A case of esophageal sarcomatoid carcinoma with molecular evidence of a monoclonal origin. Pathol Res Pract, 2001, 197(1): 41-46.
21. Ohtaka M, Kumasaka T, Nobukawa B, et al. Carcinosarcoma of the esophagus characterized by myoepithelial and ductal differentiations. Pathol Int, 2002, 52(10): 657-663.
22. Lam KY, Law SY, Loke SL, et al. Double sarcomatoid carcinomas of the oesophagus. Pathol Res Pract, 1996, 192(6): 604-609.
23. Nakagawa S, Yabusaki H, Tanaka O. Rapid-growth carcinosarcoma of the esophagus arising from 0-Ⅱc squamous cell carcinoma after definitive chemoradiotherapy: a case report. Esophagus, 2009, 6(2): 123-126.
24. Ogasawara N, Tamura Y, Funaki Y, et al. Rapidly growing esophageal carcinosarcoma reduced by neoadjuvant radiotherapy alone. Case Rep Gastroenterol, 2014, 8(2): 227-234.
25. Lauwers GY, Grant LD, Scott GV, et al. Spindle cell squamous carcinoma of the esophagus: analysis of ploidy and tumor proliferative activity in a series of 13 cases. Hum Pathol, 1998, 29(8): 863-868.
26. 许丰, 吴杨庆, 马涵, 等. 食管肉瘤样癌内镜切除的临床价值初步探讨. 中华消化内镜杂志, 2016, 33(5): 334-336.
27. Zuiki T, Hosoya Y, Ui T, et al. Therapeutic effectiveness of chemoradiotherapy for carcinosarcoma of the esophagus: two case reports and a review of the literature. Esophagus, 2009, 6(3): 189-195.
28. Kobayashi D, Koike M, Kodera Y, et al. Carcinosarcoma of the esophagus treated with chemoradiotherapy: report of four cases. Esophagus, 2010, 7(2): 119-125.
29. Joseph RW, Millis SZ, Carballido EM, et al. PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation. Cancer immunology research, 2015, 3(12): 1303-1307.
30. Vieira T, Antoine M, Hamard C, et al. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer, 2016, 98: 51-58.
31. Velcheti V, Rimm DL, Schalper KA. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) J Thorac Oncol, 2013, 8(6): 803-805.
32. Kim S, Kim MY, Koh J, et al. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas. Eur J Cancer, 2015, 51(17): 2698-2707.
33. Pelosi G, Gasparini P, Conte D, et al. Synergistic activation upon Met and ALK coamplification sustains targeted therapy in sarcomatoid carcinoma, a deadly subtype of lung cancer. J Thorac Oncol, 2016, 11(5): 718-728.
34. Zhang HL, Zhu Y, Qin XJ, et al. c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature. Clin Genitourin Cancer, 2013, 11(2): 134-140.
35. Geynisman DM. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur Urol, 2015, 68(5): 912-914.

Previous Article
微 RNA 在乙型肝炎相关疾病中作用研究进展
Next Article
激素类抗肿瘤药物的超说明书用药进展

West China Medical Journal

食管肉瘤样癌诊治现状

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content